Corcept Therapeutics Incorporated (CORT) News

Corcept Therapeutics Incorporated (CORT): $25.44

1.66 (+6.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CORT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter CORT News Items

CORT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CORT News Highlights

  • CORT's 30 day story count now stands at 19.
  • Over the past 23 days, the trend for CORT's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • BEAT, LINK and CERE are the most mentioned tickers in articles about CORT.

Latest CORT News From Around the Web

Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.

3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin

When it comes to high-flying cryptocurrencies, Shiba Inu (CRYPTO: SHIB) is among the most visible. Fueled by a frenzy of speculative buying late last year, the cheerful memes minted by the coin's community, known as the Shiba Army, are doubtlessly one of its enduring appeals. On the other hand, you probably haven't heard of Corcept Therapeutics (NASDAQ: CORT), a biotech company that's worth just over $2.6 billion.

Yahoo | February 23, 2022

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff On Q4 2021 Results - Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q4 2021 Results Conference Call February 15, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Bill Guyer - Chief Development Officer Conference Call Participants...

SA Transcripts on Seeking Alpha | February 16, 2022

Analysts’ Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks.

Brian Anderson on TipRanks | February 16, 2022

Corcept Therapeutics (CORT) Q4 2021 Earnings Call Transcript

CORT earnings call for the period ending December 31, 2021.

The Motley Fool | February 16, 2022

Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss

Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.

Yahoo | February 16, 2022

Corcept Therapeutics Incorporated 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Corcept Therapeutics Incorporated in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 15, 2022

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021.

GlobeNewswire | February 15, 2022

Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates

Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 15, 2022

Corcept Therapeutics Q4 2021 Earnings Preview

Corcept Therapeutics (NASDAQ:CORT) is scheduled to announce Q4 earnings results on Tuesday, Feb. 15, after market close.The consensus EPS estimate is $0.35

Seeking Alpha | February 14, 2022

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

With its stock down 13% over the past three months, it is easy to disregard Corcept Therapeutics (NASDAQ:CORT...

Yahoo | February 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6251 seconds.